Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-3.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
3
Industry P/E
--
EV/EBITDA
-0.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-1.1
Face value
--
Shares outstanding
39,744,200
CFO
$-311.86 Mln
EBITDA
$-241.48 Mln
Net Profit
$-533.13 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Viracta Therapeutics (VIRX)
| -89.4 | -- | -51.7 | -98.0 | -79.1 | -73.8 | -64.4 |
|
BSE Sensex
| 5.2 | 7.3 | 8.4 | 12.8 | 16.0 | 21.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Viracta Therapeutics (VIRX)
| -71.5 | -61.0 | -60.0 | 83.4 | -41.5 | -19.0 | -88.5 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Viracta Therapeutics (VIRX)
|
0.0 | 0.8 | 0.7 | -43.3 | -5,434.4 | -- | -- | 3.0 |
| 49.2 | 7,502.9 | 1,196.0 | 158.1 | 19.6 | 7.6 | 57.7 | 4.0 | |
| 101.7 | 6,297.4 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 18.4 | |
| 141.0 | 6,923.8 | 4,022.6 | -31.6 | 3.7 | -1.1 | 618.4 | 2.1 | |
| 56.4 | 10,350.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 45.4 | 12,304.8 | 2,168.7 | 521.3 | 31.8 | 23.1 | 25.4 | 4.5 | |
| 52.0 | 8,204.1 | 1,084.3 | 485.4 | 43.3 | 103.8 | 17.7 | 16.8 | |
| 305.7 | 8,384.8 | 2,156.6 | 416.4 | 15.6 | 56.5 | 22.3 | 14.1 | |
| 24.9 | 9,289.5 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 121.0 | 11,755.2 | 2,412.6 | 305.8 | 20.5 | 11.6 | 40.3 | 4.6 |
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of... its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California. Read more
CEO, President & Director
Mr. Mark Andrew Rothera
CEO, President & Director
Mr. Mark Andrew Rothera
Headquarters
Cardiff, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Viracta Therapeutics Inc (VIRX) stood at $ 51 Mln as on 30-Sep-24
The share price of Viracta Therapeutics Inc (VIRX) is $0.02 (NASDAQ) as of 16-May-2025 13:49 EDT. Viracta Therapeutics Inc (VIRX) has given a return of -79.13% in the last 3 years.
Viracta Therapeutics Inc (VIRX) has a market capitalisation of $ 1 Mln as on 09-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Viracta Therapeutics Inc (VIRX) is 3.00 times as on 09-May-2025, a 38% premium to its peers’ median range of 2.18 times.
Since, TTM earnings of Viracta Therapeutics Inc (VIRX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Viracta Therapeutics Inc (VIRX) and enter the required number of quantities and click on buy to purchase the shares of Viracta Therapeutics Inc (VIRX).
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.
The CEO & director of Mr. Mark Andrew Rothera. is Viracta Therapeutics Inc (VIRX), and CFO & Sr. VP is Mr. Mark Andrew Rothera.
There is no promoter pledging in Viracta Therapeutics Inc (VIRX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,230
|
|
|
1,176
|
|
|
1,035
|
|
|
929
|
|
|
838
|
|
|
820
|
|
|
750
|
|
|
682
|
|
|
630
|
| Viracta Therapeutics Inc. (VIRX) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-5434.42
|
|
Net Margin(%)
|
-5865.72
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Viracta Therapeutics Inc (VIRX) was $0 Mln.
$-0.02
(
